Jordan Lindsey: the financial trading guru

A forex Trading individual ought to have one primary fundamental attribute of identifying and isolating market trends. The prime method used to determine these market trends is by the use of a terminology called moving averages. Moving averages only show the presence or existence as well as confirmation of market trends.

The Forex Trading market tends to shift in trends but not using stock markets. The forex market is handled and run by patterns that are macroeconomic which usually take some years to be done. The market tends typically are better manifested by themselves using some duos or pairs. Some of these pairs include Euro/US Dollar as well as US Dollar/ Japanese Yen.

Market traders usually use the long-term aspect when trading if using the Forex Trading Market. The traders use the 3-SMA Filter moving average to gauge the direction as well as the strength of the market trend. The said filter is formed by inputting three different moving averages on a chart namely; a short-term that is a short period SMA trend, an intermediate term, and a long-term which shows an extended period SMA trend. If the three are in a one alignment direction, then that reveals a strong market trend.

In the case of Initial Coin Offerings commonly known as ICO, there are five major trends in play. The first trend entails the new structures for pricing and bonuses; here companies are allowed limited funding into the market. The second trend is the product funding through ICO. The third is a Wider ICO adoption due to established limitation thus foster competition. The fourth and fifth trend entails the trustworthiness of ICO improving and joining of classic investors to ICO.

Jordan Lindsey is the founder and owner of his company called Bitcoin Growth Bot. he has a track record history in the financial market with skills in equity, Blockchain management as well as control of assets.

Jordan Lindsey also founded and started JCL Capital. He is an avid algorithm trader with vast experience in the financial as well as technological sector. Jordan is a programmer and system architect. He attended the St. Joseph’s College and had studied in the Mount Angel Seminary. He hails from New York City.

Jordan Lindsey’s work experience entails; CEO at Private Information Services Incorporated as well as the founder of JCL Capital and Energy Global Advisor since 2017. He was also a VP at Maximum Capital Management Incorporated.

https://interview.net/jordan-lindsey/

Kerrisdale Capital Releases Negative Report on Proteostasis Therapeutics, Inc.

Sahm Adrangi’s company, Kerrisdale Capital, released a unfavorable report on some of the recent findings of the Proteostasis Therapeutics, Inc. company. Proteostasis Therapeutics, Inc. (PTI) is a biopharmaceutical company that works to develop new drugs and test them clinically. PTI’s lead drug in development is called PTI-428. This drug is intended to treat the effects of cystic fibrosis by boosting the messenger RNA and proteins to the CFTR gene that is believed to cause these debilitating effects, effects which are eventually fatal.

In December, PTI released results from a trial that seemed to show the drug was working. The stock market responded to these findings with approximately a 100% jump in the company’s stock prices. The FDA even granted the drug a “breakthrough therapy” designation based on the report. Sahm Adrangi’s firm decided to take a closer look at the results of the trial. The trial seemed to show the effectiveness of the drug when it compared the test group and a placebo/control group. The report released by Sahm Adrangi’s firm, Kerrisdale Capital, said that the the test group didn’t exactly do unusually well, but that rather the control group under-performed. When compared to proper benchmarks, the drug actually had little to no effect. The unbalanced report issued by PTI is Phase 2 of testing. Their Phase 1 report showed much the same that Kerrisdale Capital found: no statistically-proven improvement.

Sahm Adrangi founded Kerrisdale Capital in 2009 and remains its Chief Financial Officer. In the past, his firm has exposed fraudulent findings from several Chinese medical companies. Sahm Adrangi’s reports have to lead to those companies receiving enforcement actions from the Securities and Exchange Commission.

Sahm Adrangi’s report concerning PTI said the company had “little value” and that there was a 70% – 90% downside to purchasing their stock. As seen with other companies in the past, PTI may become subject to enforcement and loss of stock value due to Kerrisdale Capital taking a second look.

https://seekingalpha.com/article/4052332-conversation-former-hedge-fund-analyst-long-shares-gnc